Skip to NavigationSkip to content

Drug pricing

US pharma lobby launches legal action against the Trump administration over drug pricing proposals

US industry organisations including the Pharmaceutical Research and Manufacturers of America (PhRMA) have launched legal action against the Trump administration over its plans to lower drug prices in the US.

The Association of Community Cancer Centers (ACCC), the Global Colon Cancer Association (GCCA) and National Infusion Center Association, among others, joined PhRMA in denouncing the Trump administration’s Most Favored Nation (MFN) rule, which would the price tags for certain drugs in the US would be tied to the lowest price paid by developed nations elsewhere in the world.

Reinventing the value equation

Published on 27/04/20 at 01:06pm

There is a duty to ensure access to innovative treatments for patients with unmet need, but a health service gatekeeper must commit to efficient use of limited resources. Matt Fellows looks at how real-world evidence could be the key to reassessing how we determine the value of these drugs and ensure their swift availability.


How the intended role of generic medicines is being undermined in America

Published on 20/04/20 at 12:54pm

The introduction of a generic medicine should, in theory, incentivise companies to lower the price of the original drug, creating healthy market competition. However, loopholes in the current system are halting market entry, and questions over drug quality and generic manufacturing mar the process still further. Conor Kavanagh looks at the role of generics in the drug market, the current challenges and the solutions advised by experts.

US prescription drugs most expensive in world, analysis shows

Brand name prescription drugs cost on average 4.3 times more in the United States than in the UK, according to research from Johns Hopkins Bloomberg School of Public Health.

The findings, published in the journal Health Affairs, reveal that US brand name prescription drugs are the most highly priced in the world.

Meanwhile the research found that the longer drugs had been on the market, the more expensive they were in comparison to when they were sold in other countries.

The price of access: Can the NHS afford Orkambi?

Published on 29/04/19 at 11:43am

The impasse over access to Vertex’s Orkambi for cystic fibrosis patients in England and Wales has revealed the cracks in the NHS’ regulatory system. Matt Fellows explores where the core issues lie in the debate, and what can be done to prevent future breakdowns in communication for the good of patients.

Read the March 2019 issue of Pharmafocus online now!

Just one month to go until Brexit here in the UK, and it’s still all to play for. After months of warning the government over its need for certainty post-Brexit, the pharma and life sciences industries are nonetheless left with little option other than to keep one eye on the daily news and one set of fingers crossed.

President Trump unveils new plans to bring US drug prices in line with the rest of the world

Two weeks before the all-important midterm elections in the US, and after repeated strongly-worded promises, President Trump has unveiled an initiative to finally bring down prescription drug prices in the country.

“For decades, other countries have rigged the system so American patients are charged much more – in some cases much, much more – for the exact same drug,” he said in a speech revealing the plans. “In other words, Americans pay more so other countries can pay less. It's wrong. It's unfair.

Trump administration propose ruling requiring price transparency on TV ads

US Health and Human Services Secretary Alex Azar, has announced a proposal which would require pharma firms to include the list price of any drug paid for by Medicare or Medicaid, that cost more than $35 a month, on the adverts promoting them on television.

New group blames PBM's and hospitals for rising drug prices

A new group, organised under the banner of the Alliance to Protect Medical Innovation, is blaming hospitals and PBM’s for rising healthcare costs.

The organisation, which popped up at the end of September this year, has arisen in the midst of a wider effort to shift the blame for rising drug prices away from pharma companies and onto other players in the healthcare industry.

US House of Representatives blocks drug pricing advert bill

A ruling which would force pharmaceutical companies to disclose the price of their drugs in television advertisements has been set aside by members of the US House of Representatives.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches